Gut Liver.
2013 Nov;7(6):712-718.
Continuous Long-Term Entecavir Therapy in Naive Chronic Hepatitis B Patients Showing Partial Virologic Response
- Affiliations
-
- 1Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea. ihkimmd@jbnu.ac.kr
- 2Clinical Trial Center, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.
Abstract
- BACKGROUND/AIMS
We investigated the efficacy of continuous long-term entecavir 0.5 mg treatment in naive chronic hepatitis B patients showing a partial virologic response (PVR).
METHODS
A total of 227 patients were included. PVR was defined as a more than 1 log10 IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR; > or =20 IU/mL) at week 48. A complete virologic response (CVR) was defined as undetectable serum HBV DNA by PCR (<20 IU/mL) at week 48.
RESULTS
At week 48, the rate of the PVR was 64/227 (28.2%). Among patients with PVR, the cumulative rates of virologic response (serum HBV DNA <20 IU/mL) at weeks 96 and 144 were 45.2% and 73.8%, respectively. The cumulative rates of genotypic resistance were not significantly different between patients with a PVR and patients with a CVR (p=0.057). However, the cumulative rates of virologic breakthrough were higher in patients with PVR than in patients with CVR (4% vs 0% and 11.2% vs 0% at weeks 96 and 144, respectively; p<0.001).
CONCLUSIONS
Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.
Keyword
MeSH Terms
-
Adult
Alanine Transaminase/blood
Antiviral Agents/*administration & dosage
DNA, Viral/*blood
Drug Resistance, Viral/genetics
Female
Guanine/administration & dosage/*analogs & derivatives
Hepatitis B e Antigens/blood
*Hepatitis B virus/genetics
Hepatitis B, Chronic/*drug therapy
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Viral Load
Alanine Transaminase
Antiviral Agents
DNA, Viral
Guanine
Hepatitis B e Antigens
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
- Efficacy of prolonged entecavir monotherapy in treatment-naive chronic hepatitis B patients exhibiting a partial virologic response to entecavir
- Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B
- Clinical Efficacy of Entecavir and Factors Predicting Long-Term Treatment Response in Nucleoside-Naive Patients with Chronic Hepatitis B
- Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B
